$NXL

RedChip Companies will air interviews with Anixa Biosciences (NASDAQ:ANIX) and Nexalin Technology (NASDAQ:NXL) on Bloomberg TV and CNBC. Anixa is developing a breast cancer vaccine, while Nexalin focuses on neurostimulation for mental health. Both companies are preparing for key trials and commercialization efforts.

Nexalin Technology (NXL) reported new cognitive improvements in Alzheimer's patients using its Gen-2 SYNC DIFS device, based on a secondary analysis of trial data. 10 of 20 participants showed meaningful improvements in memory and language. The company plans a U.S. pilot study incorporating these findings. NXL stock is currently at $5.44, down 12.12%.

Nexalin Technology, Inc. (NXL) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Direct ors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On August 28, 2026, Carolyn Shelton departed from her role as Senior Vice President of Quality, Regulatory, and Clinical A

Nexalin Technology (NXL) announced a 1-for-30 reverse stock split, effective August 28, 2026, to comply with Nasdaq's bid-price rule. Trading will resume on August 31 under the same ticker. The company develops neurostimulation products for mental health.

Nexalin Technology, Inc. (NXL) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. On August 21, 2026, Nexalin Technology, Inc. (the “Company”) entered into a Note Purchase Agreement (the “Note Purchase Agreement”) with an institutional investor (the “Investor”), pursuant to which the Investor purchased from

Nexalin Technology, Inc. (NXL) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. Securities Purchase Agreement On August 19, 2026, Nexalin Technology, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with a single institutional investor (the “Investor”), pursuant

Nexalin Technology, Inc. (NXL) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. Item 5.07 Submission of Maters to a Vote of Security Holders. The annual meeting (the “Annual Meeting”) of the stockholders of Nexalin Technology, Inc. (the “Company”) was convened at 10:00 a.m. Eastern time on August 11, 2026. Of the 22,011,302 shares of the Company’s common sto

Nexalin Technology, Inc. (NXL) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. On July 28, 2026, Nexalin Technology, Inc. (the “Company”) entered into a Third Amendment to Office Lease (the “Third Amendment”) with Nutex HQ LLC (“Landlord”), which amends that certain Office Lease from 2012, as previously

Nexalin Technology (NXL) reported positive eight-week clinical trial results for its non-invasive DIFS neurostimulation in adults with generalized anxiety disorder and comorbid insomnia. Conducted at the University of São Paulo’s Institute of Psychiatry, the study used a 15 mA, 77.5 Hz protocol across 20 40-minute sessions. Nexalin said the end-of-treatment anxiety response rate was 77.8% (HAM-A drop by Session 5 and maintained at follow-up), with no serious adverse events.

Nexalin Technology, Inc. praised recent bipartisan Congressional initiatives that expand federal focus on deep brain neurostimulation research within the VA and NIH. The company actively participated in shaping legislation to increase veterans' access to emerging treatments, especially those for traumatic brain injury, PTSD, stroke recovery, and Alzheimer's disease. Nexalin's DIFS™ technology is recognized as a sophisticated non-invasive neurostimulation method and is currently being evaluated in research with UC San Diego and the San Diego VA community.